|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_on1162002557 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
120802s2012 nyu ob 001 0 eng |
| 010 |
|
|
|a 2020677201
|
| 040 |
|
|
|a DLC
|b eng
|e rda
|c DLC
|d VLY
|d OCLCO
|d AZK
|d YDXCP
|d N$T
|d E7B
|d OCLCF
|d NLGGC
|d EBLCP
|d LOA
|d MERUC
|d AGLDB
|d ICA
|d MOR
|d PIFAG
|d ZCU
|d U3W
|d D6H
|d STF
|d WRM
|d VTS
|d NRAMU
|d ICG
|d VT2
|d WYU
|d DKC
|d AU@
|d M8D
|d K6U
|d UKCRE
|d AJS
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 828140625
|a 923654270
|a 961573436
|a 962684398
|a 966182436
|a 988436558
|a 992028910
|a 1037927216
|a 1038665338
|a 1045509625
|a 1055383791
|a 1066451555
|a 1081210814
|a 1153513512
|
| 020 |
|
|
|a 9781619423459
|q (ebook)
|
| 020 |
|
|
|a 1619423456
|
| 020 |
|
|
|z 9781619423435
|
| 020 |
|
|
|z 161942343X
|q (hbk.)
|
| 029 |
1 |
|
|a AU@
|b 000059385624
|
| 029 |
1 |
|
|a DEBBG
|b BV041049667
|
| 029 |
1 |
|
|a DEBBG
|b BV043961304
|
| 029 |
1 |
|
|a DEBBG
|b BV044087302
|
| 029 |
1 |
|
|a DEBSZ
|b 481298959
|
| 029 |
1 |
|
|a NZ1
|b 15025247
|
| 035 |
|
|
|a (OCoLC)1162002557
|z (OCoLC)828140625
|z (OCoLC)923654270
|z (OCoLC)961573436
|z (OCoLC)962684398
|z (OCoLC)966182436
|z (OCoLC)988436558
|z (OCoLC)992028910
|z (OCoLC)1037927216
|z (OCoLC)1038665338
|z (OCoLC)1045509625
|z (OCoLC)1055383791
|z (OCoLC)1066451555
|z (OCoLC)1081210814
|z (OCoLC)1153513512
|
| 050 |
0 |
0 |
|a RM405.5
|
| 060 |
|
4 |
|a WD 305
|
| 072 |
|
7 |
|a MED
|x 044000
|2 bisacsh
|
| 082 |
0 |
0 |
|a 615.7/94
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Infliximab :
|b pharmacology, uses and limitations /
|c Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors.
|
| 264 |
|
1 |
|a New York :
|b Nova Science Publishers, Incorporated,
|c [2012]
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a data file
|2 rda
|
| 380 |
|
|
|a Bibliography
|
| 490 |
1 |
|
|a Immunology and immune system disorders
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
|
|
|a Description based on print version record.
|
| 505 |
0 |
|
|a ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use of Infliximab: Evidence""; ""4. Risk of Infection from the Use of Anti-TNF (Inflximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections""
|
| 505 |
8 |
|
|a ""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohn�s Disease ""; ""Fistulizing Crohn�s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing ""
|
| 505 |
8 |
|
|a ""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations ""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References ""; ""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract ""; ""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution ""; ""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration ""; ""2.6. Pharmacogenomics""
|
| 505 |
8 |
|
|a ""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c) Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g) Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1. Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure ""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity ""
|
| 546 |
|
|
|a English.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Infliximab.
|
| 650 |
|
0 |
|a Infliximab
|x Therapeutic use.
|
| 650 |
|
0 |
|a Anti-inflammatory agents.
|
| 650 |
|
2 |
|a Autoimmune Diseases
|x drug therapy
|
| 650 |
|
2 |
|a Anti-Inflammatory Agents
|
| 650 |
|
6 |
|a Infliximab.
|
| 650 |
|
6 |
|a Infliximab
|x Emploi en thérapeutique.
|
| 650 |
|
6 |
|a Antiinflammatoires.
|
| 650 |
|
7 |
|a MEDICAL
|x Immunology.
|2 bisacsh
|
| 650 |
|
7 |
|a Autoimmune diseases
|x Chemotherapy
|2 fast
|
| 650 |
|
7 |
|a Infliximab
|2 fast
|
| 700 |
1 |
|
|a Medrano Acevedo, Antonio D.
|
| 700 |
1 |
|
|a Fajardo Gaitan, Montserrat.
|
| 776 |
0 |
8 |
|i Print version:
|t Infliximab
|d [Hauppauge] New York : Nova Science Publishers, Inc., [2012]
|z 9781619423435
|w (DLC) 2012418415
|
| 830 |
|
0 |
|a Immunology and immune system disorders.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=540914
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL3017947
|
| 938 |
|
|
|a ebrary
|b EBRY
|n ebr10654918
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 540914
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 7252252
|
| 994 |
|
|
|a 92
|b IZTAP
|
